Corporate
2022.05.24
Lumosa Participating the 2022 BIO International Convention
Corporate
2022.03.25
Taiwan FDA Approved the Phase 2 IND for Multiple-dosing of LT3001
Corporate
2022.03.15
Lumosa to Attend Bio-Europe Spring
Corporate
2022.01.27
Lumosa to Present LT3001 at the International Stroke Conference 2022
Corporate
2022.01.11
Lumosa Receives U.S. FDA Fast Track Designation for Its LT3001, a Novel Drug for the Treatment of Acute Ischemic Stroke
Corporate
2021.12.29
Lumosa Receives Market Approval for Its Long-Acting Analgesic Injection from Thailand